Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Aptose Biosciences ( (TSE:APS) ) has shared an announcement.
On June 20, 2025, Aptose Biosciences Inc. announced a loan agreement with Hanmi Pharmaceutical Co. Ltd. for up to $8.5 million to support the clinical development of a Tuspetinib-based therapy for newly diagnosed acute myeloid leukemia and related business operations. The loan, which must be fully repaid by August 31, 2028, includes various financial covenants and is secured by a first-ranking security interest over the company’s assets, potentially impacting the company’s financial strategy and stakeholder interests.
The most recent analyst rating on (TSE:APS) stock is a Buy with a C$60.00 price target. To see the full list of analyst forecasts on Aptose Biosciences stock, see the TSE:APS Stock Forecast page.
Spark’s Take on TSE:APS Stock
According to Spark, TipRanks’ AI Analyst, TSE:APS is a Underperform.
Aptose Biosciences faces significant financial distress with no revenue generation and substantial losses. The negative technical indicators and valuation metrics further highlight the stock’s weak position. However, recent corporate events provide a glimmer of hope with potential advancements in AML treatment and strategic partnerships, slightly mitigating the overall risks. The stock remains risky, requiring cautious optimism for future developments.
To see Spark’s full report on TSE:APS stock, click here.
More about Aptose Biosciences
Aptose Biosciences Inc. operates in the biotechnology industry, focusing on the development of innovative therapies for the treatment of cancer. Its primary product is Tuspetinib, a drug aimed at treating acute myeloid leukemia (AML).
Average Trading Volume: 7,780
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$2.83M
For an in-depth examination of APS stock, go to TipRanks’ Overview page.